环孢霉素A联合重组人白介素-11治疗难治性特发性血小板减少性紫癜的疗效分析  

Analysis of treatment efficacy of cyclosporine A combined with human recombinant interleukin-11 in refractory immune thrombocytopenic purpura

作　　者：杨国雷[1] 张复华[1] 凌奕文[1] 牛国敏[1] 

机构地区：[1]南方医科大学附属南海医院,528200

出　　处：《中国现代药物应用》2013年第21期15-16,共2页Chinese Journal of Modern Drug Application

摘　　要：目的探讨环孢霉素A(CSA)联合重组人白介素-11(IL-11)治疗难治性特发性血小板减少性紫癜的疗效。方法对37例难治性ITP患者分为观察组与对照组。观察组:注射用重组人白介素-11(巨和粒)30μg/(kg·d),疗程14 d;环孢霉素A 5 mg/(kg·d),6个月;对照组:环孢霉素A 5 mg/(kg·d),6个月。结果观察组有效率为91%,对照组有效率为63%,两组差异有统计学意义(P<0.05)。结论环孢霉素A联合重组人白介素-11治疗难治性特发性血小板减少性紫癜疗效好,不良反应可接受。Objective To discuss the treatment efficacy of cyclosporine A （CSA） combined with human recombinant interleukin-11 （ IL-11 ） in refractory immune thrembocytopenic purpura. Methods All 37 patients diagnosed as refractory immune thrembocytopenic purpura were divided into observation group and control group. Observation group： IL-11 [30 μg/（kg · d）] and CSA [5 mg/（kg ·d）] were added. Control group： only CSA [ 5 mg/（ kg · d） ] was added. The observation time was six months. Results The effective rates were 91% and 63% in Observation group and Control group, respectively. The difference was significant （P 〈 0. 05）. Conclusion CSA combined with IL-11 had good treatment efficacy and security in refractory immune thrombocytopenic purpura.

关 键 词：ITP 难治性 环孢霉素A 白介素-11 

分 类 号：R554.6[医药卫生—血液循环系统疾病]